Global Follicular Lymphoma Drugs Market 2025 by Company, Regions, Type and Application, Forecast to 2031
According to our (Global Info Research) latest study, the global Follicular Lymphoma Drugs market size was valued at US$ 1902 million in 2024 and is forecast to a readjusted size of USD 3083 million by 2031 with a CAGR of 7.2% during review period.
Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.
Global core follicular lymphoma drugs players include Roche, Teva and Bayer etc. The Top3 companies hold a share about 57%. North America is the largest market, with a share about 58%, followed by Europe and Asia Pacific with the share about 21% and 20%.
This report is a detailed and comprehensive analysis for global Follicular Lymphoma Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Administration Route. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Follicular Lymphoma Drugs market size and forecasts, in consumption value ($ Million), 2020-2031
Global Follicular Lymphoma Drugs market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Follicular Lymphoma Drugs market size and forecasts, by Type and by Administration Route, in consumption value ($ Million), 2020-2031
Global Follicular Lymphoma Drugs market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Follicular Lymphoma Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Follicular Lymphoma Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Gilead Sciences, TG Therapeutics, Bayer, Secura Bio, Epizyme, Eisai, Acrotech Biopharma, Teva, Eagle Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Follicular Lymphoma Drugs market is split by Type and by Administration Route. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Administration Route. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Follicular Lymphoma Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Follicular Lymphoma Drugs, with revenue, gross margin, and global market share of Follicular Lymphoma Drugs from 2020 to 2025.
Chapter 3, the Follicular Lymphoma Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Administration Route, with consumption value and growth rate by Type, by Administration Route, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Follicular Lymphoma Drugs market forecast, by regions, by Type and by Administration Route, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Follicular Lymphoma Drugs.
Chapter 13, to describe Follicular Lymphoma Drugs research findings and conclusion.
Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.
Global core follicular lymphoma drugs players include Roche, Teva and Bayer etc. The Top3 companies hold a share about 57%. North America is the largest market, with a share about 58%, followed by Europe and Asia Pacific with the share about 21% and 20%.
This report is a detailed and comprehensive analysis for global Follicular Lymphoma Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Administration Route. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Follicular Lymphoma Drugs market size and forecasts, in consumption value ($ Million), 2020-2031
Global Follicular Lymphoma Drugs market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Follicular Lymphoma Drugs market size and forecasts, by Type and by Administration Route, in consumption value ($ Million), 2020-2031
Global Follicular Lymphoma Drugs market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Follicular Lymphoma Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Follicular Lymphoma Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Gilead Sciences, TG Therapeutics, Bayer, Secura Bio, Epizyme, Eisai, Acrotech Biopharma, Teva, Eagle Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Follicular Lymphoma Drugs market is split by Type and by Administration Route. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Administration Route. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Anti-CD20 mAbs
- Chemotherapy Agents
- Kinase Inhibitor
- Others
- Injection
- Oral
- Roche
- Gilead Sciences
- TG Therapeutics
- Bayer
- Secura Bio
- Epizyme
- Eisai
- Acrotech Biopharma
- Teva
- Eagle Pharmaceuticals
- MundiPharma
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Follicular Lymphoma Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Follicular Lymphoma Drugs, with revenue, gross margin, and global market share of Follicular Lymphoma Drugs from 2020 to 2025.
Chapter 3, the Follicular Lymphoma Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Administration Route, with consumption value and growth rate by Type, by Administration Route, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Follicular Lymphoma Drugs market forecast, by regions, by Type and by Administration Route, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Follicular Lymphoma Drugs.
Chapter 13, to describe Follicular Lymphoma Drugs research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Follicular Lymphoma Drugs by Type
1.3.1 Overview: Global Follicular Lymphoma Drugs Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Follicular Lymphoma Drugs Consumption Value Market Share by Type in 2024
1.3.3 Anti-CD20 mAbs
1.3.4 Chemotherapy Agents
1.3.5 Kinase Inhibitor
1.3.6 Others
1.4 Global Follicular Lymphoma Drugs Market by Administration Route
1.4.1 Overview: Global Follicular Lymphoma Drugs Market Size by Administration Route: 2020 Versus 2024 Versus 2031
1.4.2 Injection
1.4.3 Oral
1.5 Global Follicular Lymphoma Drugs Market Size & Forecast
1.6 Global Follicular Lymphoma Drugs Market Size and Forecast by Region
1.6.1 Global Follicular Lymphoma Drugs Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Follicular Lymphoma Drugs Market Size by Region, (2020-2031)
1.6.3 North America Follicular Lymphoma Drugs Market Size and Prospect (2020-2031)
1.6.4 Europe Follicular Lymphoma Drugs Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Follicular Lymphoma Drugs Market Size and Prospect (2020-2031)
1.6.6 South America Follicular Lymphoma Drugs Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Follicular Lymphoma Drugs Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Follicular Lymphoma Drugs Product and Solutions
2.1.4 Roche Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Roche Recent Developments and Future Plans
2.2 Gilead Sciences
2.2.1 Gilead Sciences Details
2.2.2 Gilead Sciences Major Business
2.2.3 Gilead Sciences Follicular Lymphoma Drugs Product and Solutions
2.2.4 Gilead Sciences Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Gilead Sciences Recent Developments and Future Plans
2.3 TG Therapeutics
2.3.1 TG Therapeutics Details
2.3.2 TG Therapeutics Major Business
2.3.3 TG Therapeutics Follicular Lymphoma Drugs Product and Solutions
2.3.4 TG Therapeutics Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 TG Therapeutics Recent Developments and Future Plans
2.4 Bayer
2.4.1 Bayer Details
2.4.2 Bayer Major Business
2.4.3 Bayer Follicular Lymphoma Drugs Product and Solutions
2.4.4 Bayer Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Bayer Recent Developments and Future Plans
2.5 Secura Bio
2.5.1 Secura Bio Details
2.5.2 Secura Bio Major Business
2.5.3 Secura Bio Follicular Lymphoma Drugs Product and Solutions
2.5.4 Secura Bio Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Secura Bio Recent Developments and Future Plans
2.6 Epizyme
2.6.1 Epizyme Details
2.6.2 Epizyme Major Business
2.6.3 Epizyme Follicular Lymphoma Drugs Product and Solutions
2.6.4 Epizyme Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Epizyme Recent Developments and Future Plans
2.7 Eisai
2.7.1 Eisai Details
2.7.2 Eisai Major Business
2.7.3 Eisai Follicular Lymphoma Drugs Product and Solutions
2.7.4 Eisai Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Eisai Recent Developments and Future Plans
2.8 Acrotech Biopharma
2.8.1 Acrotech Biopharma Details
2.8.2 Acrotech Biopharma Major Business
2.8.3 Acrotech Biopharma Follicular Lymphoma Drugs Product and Solutions
2.8.4 Acrotech Biopharma Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Acrotech Biopharma Recent Developments and Future Plans
2.9 Teva
2.9.1 Teva Details
2.9.2 Teva Major Business
2.9.3 Teva Follicular Lymphoma Drugs Product and Solutions
2.9.4 Teva Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Teva Recent Developments and Future Plans
2.10 Eagle Pharmaceuticals
2.10.1 Eagle Pharmaceuticals Details
2.10.2 Eagle Pharmaceuticals Major Business
2.10.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Product and Solutions
2.10.4 Eagle Pharmaceuticals Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Eagle Pharmaceuticals Recent Developments and Future Plans
2.11 MundiPharma
2.11.1 MundiPharma Details
2.11.2 MundiPharma Major Business
2.11.3 MundiPharma Follicular Lymphoma Drugs Product and Solutions
2.11.4 MundiPharma Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 MundiPharma Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Follicular Lymphoma Drugs Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Follicular Lymphoma Drugs by Company Revenue
3.2.2 Top 3 Follicular Lymphoma Drugs Players Market Share in 2024
3.2.3 Top 6 Follicular Lymphoma Drugs Players Market Share in 2024
3.3 Follicular Lymphoma Drugs Market: Overall Company Footprint Analysis
3.3.1 Follicular Lymphoma Drugs Market: Region Footprint
3.3.2 Follicular Lymphoma Drugs Market: Company Product Type Footprint
3.3.3 Follicular Lymphoma Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Follicular Lymphoma Drugs Consumption Value and Market Share by Type (2020-2025)
4.2 Global Follicular Lymphoma Drugs Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY ADMINISTRATION ROUTE
5.1 Global Follicular Lymphoma Drugs Consumption Value Market Share by Administration Route (2020-2025)
5.2 Global Follicular Lymphoma Drugs Market Forecast by Administration Route (2026-2031)
6 NORTH AMERICA
6.1 North America Follicular Lymphoma Drugs Consumption Value by Type (2020-2031)
6.2 North America Follicular Lymphoma Drugs Market Size by Administration Route (2020-2031)
6.3 North America Follicular Lymphoma Drugs Market Size by Country
6.3.1 North America Follicular Lymphoma Drugs Consumption Value by Country (2020-2031)
6.3.2 United States Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
6.3.3 Canada Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
6.3.4 Mexico Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Follicular Lymphoma Drugs Consumption Value by Type (2020-2031)
7.2 Europe Follicular Lymphoma Drugs Consumption Value by Administration Route (2020-2031)
7.3 Europe Follicular Lymphoma Drugs Market Size by Country
7.3.1 Europe Follicular Lymphoma Drugs Consumption Value by Country (2020-2031)
7.3.2 Germany Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
7.3.3 France Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
7.3.5 Russia Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
7.3.6 Italy Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Follicular Lymphoma Drugs Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Follicular Lymphoma Drugs Consumption Value by Administration Route (2020-2031)
8.3 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region
8.3.1 Asia-Pacific Follicular Lymphoma Drugs Consumption Value by Region (2020-2031)
8.3.2 China Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
8.3.3 Japan Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
8.3.4 South Korea Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
8.3.5 India Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
8.3.7 Australia Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Follicular Lymphoma Drugs Consumption Value by Type (2020-2031)
9.2 South America Follicular Lymphoma Drugs Consumption Value by Administration Route (2020-2031)
9.3 South America Follicular Lymphoma Drugs Market Size by Country
9.3.1 South America Follicular Lymphoma Drugs Consumption Value by Country (2020-2031)
9.3.2 Brazil Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
9.3.3 Argentina Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Follicular Lymphoma Drugs Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Follicular Lymphoma Drugs Consumption Value by Administration Route (2020-2031)
10.3 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country
10.3.1 Middle East & Africa Follicular Lymphoma Drugs Consumption Value by Country (2020-2031)
10.3.2 Turkey Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
10.3.4 UAE Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Follicular Lymphoma Drugs Market Drivers
11.2 Follicular Lymphoma Drugs Market Restraints
11.3 Follicular Lymphoma Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Follicular Lymphoma Drugs Industry Chain
12.2 Follicular Lymphoma Drugs Upstream Analysis
12.3 Follicular Lymphoma Drugs Midstream Analysis
12.4 Follicular Lymphoma Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OFTABLES
Table 1. GlobalFollicular Lymphoma Drugs Consumption Value byType, (USD Million), 2020 & 2024 & 2031
Table 2. GlobalFollicular Lymphoma Drugs Consumption Value by Administration Route, (USD Million), 2020 & 2024 & 2031
Table 3. GlobalFollicular Lymphoma Drugs Consumption Value by Region (2020-2025) & (USD Million)
Table 4. GlobalFollicular Lymphoma Drugs Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Roche Company Information, Head Office, and Major Competitors
Table 6. Roche Major Business
Table 7. RocheFollicular Lymphoma Drugs Product and Solutions
Table 8. RocheFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Roche Recent Developments andFuture Plans
Table 10. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 11. Gilead Sciences Major Business
Table 12. Gilead SciencesFollicular Lymphoma Drugs Product and Solutions
Table 13. Gilead SciencesFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Gilead Sciences Recent Developments andFuture Plans
Table 15.TGTherapeutics Company Information, Head Office, and Major Competitors
Table 16.TGTherapeutics Major Business
Table 17.TGTherapeuticsFollicular Lymphoma Drugs Product and Solutions
Table 18.TGTherapeuticsFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. Bayer Company Information, Head Office, and Major Competitors
Table 20. Bayer Major Business
Table 21. BayerFollicular Lymphoma Drugs Product and Solutions
Table 22. BayerFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. Bayer Recent Developments andFuture Plans
Table 24. Secura Bio Company Information, Head Office, and Major Competitors
Table 25. Secura Bio Major Business
Table 26. Secura BioFollicular Lymphoma Drugs Product and Solutions
Table 27. Secura BioFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. Secura Bio Recent Developments andFuture Plans
Table 29. Epizyme Company Information, Head Office, and Major Competitors
Table 30. Epizyme Major Business
Table 31. EpizymeFollicular Lymphoma Drugs Product and Solutions
Table 32. EpizymeFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Epizyme Recent Developments andFuture Plans
Table 34. Eisai Company Information, Head Office, and Major Competitors
Table 35. Eisai Major Business
Table 36. EisaiFollicular Lymphoma Drugs Product and Solutions
Table 37. EisaiFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. Eisai Recent Developments andFuture Plans
Table 39. Acrotech Biopharma Company Information, Head Office, and Major Competitors
Table 40. Acrotech Biopharma Major Business
Table 41. Acrotech BiopharmaFollicular Lymphoma Drugs Product and Solutions
Table 42. Acrotech BiopharmaFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. Acrotech Biopharma Recent Developments andFuture Plans
Table 44.Teva Company Information, Head Office, and Major Competitors
Table 45.Teva Major Business
Table 46.TevaFollicular Lymphoma Drugs Product and Solutions
Table 47.TevaFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 48.Teva Recent Developments andFuture Plans
Table 49. Eagle Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 50. Eagle Pharmaceuticals Major Business
Table 51. Eagle PharmaceuticalsFollicular Lymphoma Drugs Product and Solutions
Table 52. Eagle PharmaceuticalsFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 53. Eagle Pharmaceuticals Recent Developments andFuture Plans
Table 54. MundiPharma Company Information, Head Office, and Major Competitors
Table 55. MundiPharma Major Business
Table 56. MundiPharmaFollicular Lymphoma Drugs Product and Solutions
Table 57. MundiPharmaFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 58. MundiPharma Recent Developments andFuture Plans
Table 59. GlobalFollicular Lymphoma Drugs Revenue (USD Million) by Players (2020-2025)
Table 60. GlobalFollicular Lymphoma Drugs Revenue Share by Players (2020-2025)
Table 61. Breakdown ofFollicular Lymphoma Drugs by CompanyType (Tier 1,Tier 2, andTier 3)
Table 62. Market Position of Players inFollicular Lymphoma Drugs, (Tier 1,Tier 2, andTier 3), Based on Revenue in 2024
Table 63. Head Office of KeyFollicular Lymphoma Drugs Players
Table 64.Follicular Lymphoma Drugs Market: Company ProductTypeFootprint
Table 65.Follicular Lymphoma Drugs Market: Company Product ApplicationFootprint
Table 66.Follicular Lymphoma Drugs New Market Entrants and Barriers to Market Entry
Table 67.Follicular Lymphoma Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 68. GlobalFollicular Lymphoma Drugs Consumption Value (USD Million) byType (2020-2025)
Table 69. GlobalFollicular Lymphoma Drugs Consumption Value Share byType (2020-2025)
Table 70. GlobalFollicular Lymphoma Drugs Consumption ValueForecast byType (2026-2031)
Table 71. GlobalFollicular Lymphoma Drugs Consumption Value by Administration Route (2020-2025)
Table 72. GlobalFollicular Lymphoma Drugs Consumption ValueForecast by Administration Route (2026-2031)
Table 73. North AmericaFollicular Lymphoma Drugs Consumption Value byType (2020-2025) & (USD Million)
Table 74. North AmericaFollicular Lymphoma Drugs Consumption Value byType (2026-2031) & (USD Million)
Table 75. North AmericaFollicular Lymphoma Drugs Consumption Value by Administration Route (2020-2025) & (USD Million)
Table 76. North AmericaFollicular Lymphoma Drugs Consumption Value by Administration Route (2026-2031) & (USD Million)
Table 77. North AmericaFollicular Lymphoma Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 78. North AmericaFollicular Lymphoma Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 79. EuropeFollicular Lymphoma Drugs Consumption Value byType (2020-2025) & (USD Million)
Table 80. EuropeFollicular Lymphoma Drugs Consumption Value byType (2026-2031) & (USD Million)
Table 81. EuropeFollicular Lymphoma Drugs Consumption Value by Administration Route (2020-2025) & (USD Million)
Table 82. EuropeFollicular Lymphoma Drugs Consumption Value by Administration Route (2026-2031) & (USD Million)
Table 83. EuropeFollicular Lymphoma Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 84. EuropeFollicular Lymphoma Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 85. Asia-PacificFollicular Lymphoma Drugs Consumption Value byType (2020-2025) & (USD Million)
Table 86. Asia-PacificFollicular Lymphoma Drugs Consumption Value byType (2026-2031) & (USD Million)
Table 87. Asia-PacificFollicular Lymphoma Drugs Consumption Value by Administration Route (2020-2025) & (USD Million)
Table 88. Asia-PacificFollicular Lymphoma Drugs Consumption Value by Administration Route (2026-2031) & (USD Million)
Table 89. Asia-PacificFollicular Lymphoma Drugs Consumption Value by Region (2020-2025) & (USD Million)
Table 90. Asia-PacificFollicular Lymphoma Drugs Consumption Value by Region (2026-2031) & (USD Million)
Table 91. South AmericaFollicular Lymphoma Drugs Consumption Value byType (2020-2025) & (USD Million)
Table 92. South AmericaFollicular Lymphoma Drugs Consumption Value byType (2026-2031) & (USD Million)
Table 93. South AmericaFollicular Lymphoma Drugs Consumption Value by Administration Route (2020-2025) & (USD Million)
Table 94. South AmericaFollicular Lymphoma Drugs Consumption Value by Administration Route (2026-2031) & (USD Million)
Table 95. South AmericaFollicular Lymphoma Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 96. South AmericaFollicular Lymphoma Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 97. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value byType (2020-2025) & (USD Million)
Table 98. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value byType (2026-2031) & (USD Million)
Table 99. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value by Administration Route (2020-2025) & (USD Million)
Table 100. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value by Administration Route (2026-2031) & (USD Million)
Table 101. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 102. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 103. Global Key Players ofFollicular Lymphoma Drugs Upstream (Raw Materials)
Table 104. GlobalFollicular Lymphoma DrugsTypical Customers
LIST OFFIGURES
Figure 1.Follicular Lymphoma Drugs Picture
Figure 2. GlobalFollicular Lymphoma Drugs Consumption Value byType, (USD Million), 2020 & 2024 & 2031
Figure 3. GlobalFollicular Lymphoma Drugs Consumption Value Market Share byType in 2024
Figure 4. Anti-CD20 mAbs
Figure 5. Chemotherapy Agents
Figure 6. Kinase Inhibitor
Figure 7. Others
Figure 8. GlobalFollicular Lymphoma Drugs Consumption Value by Administration Route, (USD Million), 2020 & 2024 & 2031
Figure 9.Follicular Lymphoma Drugs Consumption Value Market Share by Administration Route in 2024
Figure 10. Injection Picture
Figure 11. Oral Picture
Figure 12. GlobalFollicular Lymphoma Drugs Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 13. GlobalFollicular Lymphoma Drugs Consumption Value andForecast (2020-2031) & (USD Million)
Figure 14. Global MarketFollicular Lymphoma Drugs Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 15. GlobalFollicular Lymphoma Drugs Consumption Value Market Share by Region (2020-2031)
Figure 16. GlobalFollicular Lymphoma Drugs Consumption Value Market Share by Region in 2024
Figure 17. North AmericaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 18. EuropeFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 19. Asia-PacificFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 20. South AmericaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 21. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 22. CompanyThree Recent Developments andFuture Plans
Figure 23. GlobalFollicular Lymphoma Drugs Revenue Share by Players in 2024
Figure 24.Follicular Lymphoma Drugs Market Share by CompanyType (Tier 1,Tier 2, andTier 3) in 2024
Figure 25. Market Share ofFollicular Lymphoma Drugs by Player Revenue in 2024
Figure 26.Top 3Follicular Lymphoma Drugs Players Market Share in 2024
Figure 27.Top 6Follicular Lymphoma Drugs Players Market Share in 2024
Figure 28. GlobalFollicular Lymphoma Drugs Consumption Value Share byType (2020-2025)
Figure 29. GlobalFollicular Lymphoma Drugs Market ShareForecast byType (2026-2031)
Figure 30. GlobalFollicular Lymphoma Drugs Consumption Value Share by Administration Route (2020-2025)
Figure 31. GlobalFollicular Lymphoma Drugs Market ShareForecast by Administration Route (2026-2031)
Figure 32. North AmericaFollicular Lymphoma Drugs Consumption Value Market Share byType (2020-2031)
Figure 33. North AmericaFollicular Lymphoma Drugs Consumption Value Market Share by Administration Route (2020-2031)
Figure 34. North AmericaFollicular Lymphoma Drugs Consumption Value Market Share by Country (2020-2031)
Figure 35. United StatesFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 36. CanadaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 37. MexicoFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 38. EuropeFollicular Lymphoma Drugs Consumption Value Market Share byType (2020-2031)
Figure 39. EuropeFollicular Lymphoma Drugs Consumption Value Market Share by Administration Route (2020-2031)
Figure 40. EuropeFollicular Lymphoma Drugs Consumption Value Market Share by Country (2020-2031)
Figure 41. GermanyFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 42.FranceFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 43. United KingdomFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 44. RussiaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 45. ItalyFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 46. Asia-PacificFollicular Lymphoma Drugs Consumption Value Market Share byType (2020-2031)
Figure 47. Asia-PacificFollicular Lymphoma Drugs Consumption Value Market Share by Administration Route (2020-2031)
Figure 48. Asia-PacificFollicular Lymphoma Drugs Consumption Value Market Share by Region (2020-2031)
Figure 49. ChinaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 50. JapanFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 51. South KoreaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 52. IndiaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 53. Southeast AsiaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 54. AustraliaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 55. South AmericaFollicular Lymphoma Drugs Consumption Value Market Share byType (2020-2031)
Figure 56. South AmericaFollicular Lymphoma Drugs Consumption Value Market Share by Administration Route (2020-2031)
Figure 57. South AmericaFollicular Lymphoma Drugs Consumption Value Market Share by Country (2020-2031)
Figure 58. BrazilFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 59. ArgentinaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 60. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value Market Share byType (2020-2031)
Figure 61. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value Market Share by Administration Route (2020-2031)
Figure 62. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value Market Share by Country (2020-2031)
Figure 63.TurkeyFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 64. Saudi ArabiaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 65. UAEFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 66.Follicular Lymphoma Drugs Market Drivers
Figure 67.Follicular Lymphoma Drugs Market Restraints
Figure 68.Follicular Lymphoma Drugs MarketTrends
Figure 69. PortersFiveForces Analysis
Figure 70.Follicular Lymphoma Drugs Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Follicular Lymphoma Drugs by Type
1.3.1 Overview: Global Follicular Lymphoma Drugs Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Follicular Lymphoma Drugs Consumption Value Market Share by Type in 2024
1.3.3 Anti-CD20 mAbs
1.3.4 Chemotherapy Agents
1.3.5 Kinase Inhibitor
1.3.6 Others
1.4 Global Follicular Lymphoma Drugs Market by Administration Route
1.4.1 Overview: Global Follicular Lymphoma Drugs Market Size by Administration Route: 2020 Versus 2024 Versus 2031
1.4.2 Injection
1.4.3 Oral
1.5 Global Follicular Lymphoma Drugs Market Size & Forecast
1.6 Global Follicular Lymphoma Drugs Market Size and Forecast by Region
1.6.1 Global Follicular Lymphoma Drugs Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Follicular Lymphoma Drugs Market Size by Region, (2020-2031)
1.6.3 North America Follicular Lymphoma Drugs Market Size and Prospect (2020-2031)
1.6.4 Europe Follicular Lymphoma Drugs Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Follicular Lymphoma Drugs Market Size and Prospect (2020-2031)
1.6.6 South America Follicular Lymphoma Drugs Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Follicular Lymphoma Drugs Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Follicular Lymphoma Drugs Product and Solutions
2.1.4 Roche Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Roche Recent Developments and Future Plans
2.2 Gilead Sciences
2.2.1 Gilead Sciences Details
2.2.2 Gilead Sciences Major Business
2.2.3 Gilead Sciences Follicular Lymphoma Drugs Product and Solutions
2.2.4 Gilead Sciences Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Gilead Sciences Recent Developments and Future Plans
2.3 TG Therapeutics
2.3.1 TG Therapeutics Details
2.3.2 TG Therapeutics Major Business
2.3.3 TG Therapeutics Follicular Lymphoma Drugs Product and Solutions
2.3.4 TG Therapeutics Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 TG Therapeutics Recent Developments and Future Plans
2.4 Bayer
2.4.1 Bayer Details
2.4.2 Bayer Major Business
2.4.3 Bayer Follicular Lymphoma Drugs Product and Solutions
2.4.4 Bayer Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Bayer Recent Developments and Future Plans
2.5 Secura Bio
2.5.1 Secura Bio Details
2.5.2 Secura Bio Major Business
2.5.3 Secura Bio Follicular Lymphoma Drugs Product and Solutions
2.5.4 Secura Bio Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Secura Bio Recent Developments and Future Plans
2.6 Epizyme
2.6.1 Epizyme Details
2.6.2 Epizyme Major Business
2.6.3 Epizyme Follicular Lymphoma Drugs Product and Solutions
2.6.4 Epizyme Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Epizyme Recent Developments and Future Plans
2.7 Eisai
2.7.1 Eisai Details
2.7.2 Eisai Major Business
2.7.3 Eisai Follicular Lymphoma Drugs Product and Solutions
2.7.4 Eisai Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Eisai Recent Developments and Future Plans
2.8 Acrotech Biopharma
2.8.1 Acrotech Biopharma Details
2.8.2 Acrotech Biopharma Major Business
2.8.3 Acrotech Biopharma Follicular Lymphoma Drugs Product and Solutions
2.8.4 Acrotech Biopharma Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Acrotech Biopharma Recent Developments and Future Plans
2.9 Teva
2.9.1 Teva Details
2.9.2 Teva Major Business
2.9.3 Teva Follicular Lymphoma Drugs Product and Solutions
2.9.4 Teva Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Teva Recent Developments and Future Plans
2.10 Eagle Pharmaceuticals
2.10.1 Eagle Pharmaceuticals Details
2.10.2 Eagle Pharmaceuticals Major Business
2.10.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Product and Solutions
2.10.4 Eagle Pharmaceuticals Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Eagle Pharmaceuticals Recent Developments and Future Plans
2.11 MundiPharma
2.11.1 MundiPharma Details
2.11.2 MundiPharma Major Business
2.11.3 MundiPharma Follicular Lymphoma Drugs Product and Solutions
2.11.4 MundiPharma Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 MundiPharma Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Follicular Lymphoma Drugs Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Follicular Lymphoma Drugs by Company Revenue
3.2.2 Top 3 Follicular Lymphoma Drugs Players Market Share in 2024
3.2.3 Top 6 Follicular Lymphoma Drugs Players Market Share in 2024
3.3 Follicular Lymphoma Drugs Market: Overall Company Footprint Analysis
3.3.1 Follicular Lymphoma Drugs Market: Region Footprint
3.3.2 Follicular Lymphoma Drugs Market: Company Product Type Footprint
3.3.3 Follicular Lymphoma Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Follicular Lymphoma Drugs Consumption Value and Market Share by Type (2020-2025)
4.2 Global Follicular Lymphoma Drugs Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY ADMINISTRATION ROUTE
5.1 Global Follicular Lymphoma Drugs Consumption Value Market Share by Administration Route (2020-2025)
5.2 Global Follicular Lymphoma Drugs Market Forecast by Administration Route (2026-2031)
6 NORTH AMERICA
6.1 North America Follicular Lymphoma Drugs Consumption Value by Type (2020-2031)
6.2 North America Follicular Lymphoma Drugs Market Size by Administration Route (2020-2031)
6.3 North America Follicular Lymphoma Drugs Market Size by Country
6.3.1 North America Follicular Lymphoma Drugs Consumption Value by Country (2020-2031)
6.3.2 United States Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
6.3.3 Canada Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
6.3.4 Mexico Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Follicular Lymphoma Drugs Consumption Value by Type (2020-2031)
7.2 Europe Follicular Lymphoma Drugs Consumption Value by Administration Route (2020-2031)
7.3 Europe Follicular Lymphoma Drugs Market Size by Country
7.3.1 Europe Follicular Lymphoma Drugs Consumption Value by Country (2020-2031)
7.3.2 Germany Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
7.3.3 France Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
7.3.5 Russia Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
7.3.6 Italy Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Follicular Lymphoma Drugs Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Follicular Lymphoma Drugs Consumption Value by Administration Route (2020-2031)
8.3 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region
8.3.1 Asia-Pacific Follicular Lymphoma Drugs Consumption Value by Region (2020-2031)
8.3.2 China Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
8.3.3 Japan Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
8.3.4 South Korea Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
8.3.5 India Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
8.3.7 Australia Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Follicular Lymphoma Drugs Consumption Value by Type (2020-2031)
9.2 South America Follicular Lymphoma Drugs Consumption Value by Administration Route (2020-2031)
9.3 South America Follicular Lymphoma Drugs Market Size by Country
9.3.1 South America Follicular Lymphoma Drugs Consumption Value by Country (2020-2031)
9.3.2 Brazil Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
9.3.3 Argentina Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Follicular Lymphoma Drugs Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Follicular Lymphoma Drugs Consumption Value by Administration Route (2020-2031)
10.3 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country
10.3.1 Middle East & Africa Follicular Lymphoma Drugs Consumption Value by Country (2020-2031)
10.3.2 Turkey Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
10.3.4 UAE Follicular Lymphoma Drugs Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Follicular Lymphoma Drugs Market Drivers
11.2 Follicular Lymphoma Drugs Market Restraints
11.3 Follicular Lymphoma Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Follicular Lymphoma Drugs Industry Chain
12.2 Follicular Lymphoma Drugs Upstream Analysis
12.3 Follicular Lymphoma Drugs Midstream Analysis
12.4 Follicular Lymphoma Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OFTABLES
Table 1. GlobalFollicular Lymphoma Drugs Consumption Value byType, (USD Million), 2020 & 2024 & 2031
Table 2. GlobalFollicular Lymphoma Drugs Consumption Value by Administration Route, (USD Million), 2020 & 2024 & 2031
Table 3. GlobalFollicular Lymphoma Drugs Consumption Value by Region (2020-2025) & (USD Million)
Table 4. GlobalFollicular Lymphoma Drugs Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Roche Company Information, Head Office, and Major Competitors
Table 6. Roche Major Business
Table 7. RocheFollicular Lymphoma Drugs Product and Solutions
Table 8. RocheFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Roche Recent Developments andFuture Plans
Table 10. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 11. Gilead Sciences Major Business
Table 12. Gilead SciencesFollicular Lymphoma Drugs Product and Solutions
Table 13. Gilead SciencesFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Gilead Sciences Recent Developments andFuture Plans
Table 15.TGTherapeutics Company Information, Head Office, and Major Competitors
Table 16.TGTherapeutics Major Business
Table 17.TGTherapeuticsFollicular Lymphoma Drugs Product and Solutions
Table 18.TGTherapeuticsFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. Bayer Company Information, Head Office, and Major Competitors
Table 20. Bayer Major Business
Table 21. BayerFollicular Lymphoma Drugs Product and Solutions
Table 22. BayerFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. Bayer Recent Developments andFuture Plans
Table 24. Secura Bio Company Information, Head Office, and Major Competitors
Table 25. Secura Bio Major Business
Table 26. Secura BioFollicular Lymphoma Drugs Product and Solutions
Table 27. Secura BioFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. Secura Bio Recent Developments andFuture Plans
Table 29. Epizyme Company Information, Head Office, and Major Competitors
Table 30. Epizyme Major Business
Table 31. EpizymeFollicular Lymphoma Drugs Product and Solutions
Table 32. EpizymeFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Epizyme Recent Developments andFuture Plans
Table 34. Eisai Company Information, Head Office, and Major Competitors
Table 35. Eisai Major Business
Table 36. EisaiFollicular Lymphoma Drugs Product and Solutions
Table 37. EisaiFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. Eisai Recent Developments andFuture Plans
Table 39. Acrotech Biopharma Company Information, Head Office, and Major Competitors
Table 40. Acrotech Biopharma Major Business
Table 41. Acrotech BiopharmaFollicular Lymphoma Drugs Product and Solutions
Table 42. Acrotech BiopharmaFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. Acrotech Biopharma Recent Developments andFuture Plans
Table 44.Teva Company Information, Head Office, and Major Competitors
Table 45.Teva Major Business
Table 46.TevaFollicular Lymphoma Drugs Product and Solutions
Table 47.TevaFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 48.Teva Recent Developments andFuture Plans
Table 49. Eagle Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 50. Eagle Pharmaceuticals Major Business
Table 51. Eagle PharmaceuticalsFollicular Lymphoma Drugs Product and Solutions
Table 52. Eagle PharmaceuticalsFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 53. Eagle Pharmaceuticals Recent Developments andFuture Plans
Table 54. MundiPharma Company Information, Head Office, and Major Competitors
Table 55. MundiPharma Major Business
Table 56. MundiPharmaFollicular Lymphoma Drugs Product and Solutions
Table 57. MundiPharmaFollicular Lymphoma Drugs Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 58. MundiPharma Recent Developments andFuture Plans
Table 59. GlobalFollicular Lymphoma Drugs Revenue (USD Million) by Players (2020-2025)
Table 60. GlobalFollicular Lymphoma Drugs Revenue Share by Players (2020-2025)
Table 61. Breakdown ofFollicular Lymphoma Drugs by CompanyType (Tier 1,Tier 2, andTier 3)
Table 62. Market Position of Players inFollicular Lymphoma Drugs, (Tier 1,Tier 2, andTier 3), Based on Revenue in 2024
Table 63. Head Office of KeyFollicular Lymphoma Drugs Players
Table 64.Follicular Lymphoma Drugs Market: Company ProductTypeFootprint
Table 65.Follicular Lymphoma Drugs Market: Company Product ApplicationFootprint
Table 66.Follicular Lymphoma Drugs New Market Entrants and Barriers to Market Entry
Table 67.Follicular Lymphoma Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 68. GlobalFollicular Lymphoma Drugs Consumption Value (USD Million) byType (2020-2025)
Table 69. GlobalFollicular Lymphoma Drugs Consumption Value Share byType (2020-2025)
Table 70. GlobalFollicular Lymphoma Drugs Consumption ValueForecast byType (2026-2031)
Table 71. GlobalFollicular Lymphoma Drugs Consumption Value by Administration Route (2020-2025)
Table 72. GlobalFollicular Lymphoma Drugs Consumption ValueForecast by Administration Route (2026-2031)
Table 73. North AmericaFollicular Lymphoma Drugs Consumption Value byType (2020-2025) & (USD Million)
Table 74. North AmericaFollicular Lymphoma Drugs Consumption Value byType (2026-2031) & (USD Million)
Table 75. North AmericaFollicular Lymphoma Drugs Consumption Value by Administration Route (2020-2025) & (USD Million)
Table 76. North AmericaFollicular Lymphoma Drugs Consumption Value by Administration Route (2026-2031) & (USD Million)
Table 77. North AmericaFollicular Lymphoma Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 78. North AmericaFollicular Lymphoma Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 79. EuropeFollicular Lymphoma Drugs Consumption Value byType (2020-2025) & (USD Million)
Table 80. EuropeFollicular Lymphoma Drugs Consumption Value byType (2026-2031) & (USD Million)
Table 81. EuropeFollicular Lymphoma Drugs Consumption Value by Administration Route (2020-2025) & (USD Million)
Table 82. EuropeFollicular Lymphoma Drugs Consumption Value by Administration Route (2026-2031) & (USD Million)
Table 83. EuropeFollicular Lymphoma Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 84. EuropeFollicular Lymphoma Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 85. Asia-PacificFollicular Lymphoma Drugs Consumption Value byType (2020-2025) & (USD Million)
Table 86. Asia-PacificFollicular Lymphoma Drugs Consumption Value byType (2026-2031) & (USD Million)
Table 87. Asia-PacificFollicular Lymphoma Drugs Consumption Value by Administration Route (2020-2025) & (USD Million)
Table 88. Asia-PacificFollicular Lymphoma Drugs Consumption Value by Administration Route (2026-2031) & (USD Million)
Table 89. Asia-PacificFollicular Lymphoma Drugs Consumption Value by Region (2020-2025) & (USD Million)
Table 90. Asia-PacificFollicular Lymphoma Drugs Consumption Value by Region (2026-2031) & (USD Million)
Table 91. South AmericaFollicular Lymphoma Drugs Consumption Value byType (2020-2025) & (USD Million)
Table 92. South AmericaFollicular Lymphoma Drugs Consumption Value byType (2026-2031) & (USD Million)
Table 93. South AmericaFollicular Lymphoma Drugs Consumption Value by Administration Route (2020-2025) & (USD Million)
Table 94. South AmericaFollicular Lymphoma Drugs Consumption Value by Administration Route (2026-2031) & (USD Million)
Table 95. South AmericaFollicular Lymphoma Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 96. South AmericaFollicular Lymphoma Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 97. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value byType (2020-2025) & (USD Million)
Table 98. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value byType (2026-2031) & (USD Million)
Table 99. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value by Administration Route (2020-2025) & (USD Million)
Table 100. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value by Administration Route (2026-2031) & (USD Million)
Table 101. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value by Country (2020-2025) & (USD Million)
Table 102. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value by Country (2026-2031) & (USD Million)
Table 103. Global Key Players ofFollicular Lymphoma Drugs Upstream (Raw Materials)
Table 104. GlobalFollicular Lymphoma DrugsTypical Customers
LIST OFFIGURES
Figure 1.Follicular Lymphoma Drugs Picture
Figure 2. GlobalFollicular Lymphoma Drugs Consumption Value byType, (USD Million), 2020 & 2024 & 2031
Figure 3. GlobalFollicular Lymphoma Drugs Consumption Value Market Share byType in 2024
Figure 4. Anti-CD20 mAbs
Figure 5. Chemotherapy Agents
Figure 6. Kinase Inhibitor
Figure 7. Others
Figure 8. GlobalFollicular Lymphoma Drugs Consumption Value by Administration Route, (USD Million), 2020 & 2024 & 2031
Figure 9.Follicular Lymphoma Drugs Consumption Value Market Share by Administration Route in 2024
Figure 10. Injection Picture
Figure 11. Oral Picture
Figure 12. GlobalFollicular Lymphoma Drugs Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 13. GlobalFollicular Lymphoma Drugs Consumption Value andForecast (2020-2031) & (USD Million)
Figure 14. Global MarketFollicular Lymphoma Drugs Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 15. GlobalFollicular Lymphoma Drugs Consumption Value Market Share by Region (2020-2031)
Figure 16. GlobalFollicular Lymphoma Drugs Consumption Value Market Share by Region in 2024
Figure 17. North AmericaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 18. EuropeFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 19. Asia-PacificFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 20. South AmericaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 21. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 22. CompanyThree Recent Developments andFuture Plans
Figure 23. GlobalFollicular Lymphoma Drugs Revenue Share by Players in 2024
Figure 24.Follicular Lymphoma Drugs Market Share by CompanyType (Tier 1,Tier 2, andTier 3) in 2024
Figure 25. Market Share ofFollicular Lymphoma Drugs by Player Revenue in 2024
Figure 26.Top 3Follicular Lymphoma Drugs Players Market Share in 2024
Figure 27.Top 6Follicular Lymphoma Drugs Players Market Share in 2024
Figure 28. GlobalFollicular Lymphoma Drugs Consumption Value Share byType (2020-2025)
Figure 29. GlobalFollicular Lymphoma Drugs Market ShareForecast byType (2026-2031)
Figure 30. GlobalFollicular Lymphoma Drugs Consumption Value Share by Administration Route (2020-2025)
Figure 31. GlobalFollicular Lymphoma Drugs Market ShareForecast by Administration Route (2026-2031)
Figure 32. North AmericaFollicular Lymphoma Drugs Consumption Value Market Share byType (2020-2031)
Figure 33. North AmericaFollicular Lymphoma Drugs Consumption Value Market Share by Administration Route (2020-2031)
Figure 34. North AmericaFollicular Lymphoma Drugs Consumption Value Market Share by Country (2020-2031)
Figure 35. United StatesFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 36. CanadaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 37. MexicoFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 38. EuropeFollicular Lymphoma Drugs Consumption Value Market Share byType (2020-2031)
Figure 39. EuropeFollicular Lymphoma Drugs Consumption Value Market Share by Administration Route (2020-2031)
Figure 40. EuropeFollicular Lymphoma Drugs Consumption Value Market Share by Country (2020-2031)
Figure 41. GermanyFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 42.FranceFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 43. United KingdomFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 44. RussiaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 45. ItalyFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 46. Asia-PacificFollicular Lymphoma Drugs Consumption Value Market Share byType (2020-2031)
Figure 47. Asia-PacificFollicular Lymphoma Drugs Consumption Value Market Share by Administration Route (2020-2031)
Figure 48. Asia-PacificFollicular Lymphoma Drugs Consumption Value Market Share by Region (2020-2031)
Figure 49. ChinaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 50. JapanFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 51. South KoreaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 52. IndiaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 53. Southeast AsiaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 54. AustraliaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 55. South AmericaFollicular Lymphoma Drugs Consumption Value Market Share byType (2020-2031)
Figure 56. South AmericaFollicular Lymphoma Drugs Consumption Value Market Share by Administration Route (2020-2031)
Figure 57. South AmericaFollicular Lymphoma Drugs Consumption Value Market Share by Country (2020-2031)
Figure 58. BrazilFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 59. ArgentinaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 60. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value Market Share byType (2020-2031)
Figure 61. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value Market Share by Administration Route (2020-2031)
Figure 62. Middle East & AfricaFollicular Lymphoma Drugs Consumption Value Market Share by Country (2020-2031)
Figure 63.TurkeyFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 64. Saudi ArabiaFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 65. UAEFollicular Lymphoma Drugs Consumption Value (2020-2031) & (USD Million)
Figure 66.Follicular Lymphoma Drugs Market Drivers
Figure 67.Follicular Lymphoma Drugs Market Restraints
Figure 68.Follicular Lymphoma Drugs MarketTrends
Figure 69. PortersFiveForces Analysis
Figure 70.Follicular Lymphoma Drugs Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
